These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15255813)

  • 1. AT(1)-receptor blockade and sympathetic neurotransmission in cardiovascular disease.
    Nap A; Balt JC; Mathy MJ; Van Zwieten PA
    Auton Autacoid Pharmacol; 2003; 23(5-6):285-96. PubMed ID: 15255813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired neuronal and vascular responses to angiotensin II in a rabbit congestive heart failure model.
    Nap A; Belterman CN; Mathy MJ; Balt JC; Pfaffendorf M; van Zwieten PA
    J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):220-7. PubMed ID: 14689369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of antihypertensive therapies on the sympathetic nervous system.
    de Champlain J; Karas M; Toal C; Nadeau R; Larochelle P
    Can J Cardiol; 1999 Mar; 15 Suppl A():8A-14A. PubMed ID: 10205251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium antagonists and sympathetic nerve activation: are there differences between classes?
    Noll G; Wenzel RR; Shaw S; Lüscher TF
    J Hypertens Suppl; 1998 Jan; 16(1):S17-24. PubMed ID: 9534092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular consequences of sympathetic hyperactivity.
    Leenen FH
    Can J Cardiol; 1999 Mar; 15 Suppl A():2A-7A. PubMed ID: 10205250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between the adrenergic and renin-angiotensin-aldosterone-systems.
    van Zwieten PA; de Jonge A
    Postgrad Med J; 1986; 62 Suppl 1():23-7. PubMed ID: 3534860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiation in the effects of the angiotensin II receptor blocker class on autonomic function.
    Esler M
    J Hypertens Suppl; 2002 Jun; 20(5):S13-9. PubMed ID: 12184059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to explain the differences between renin angiotensin system modulators.
    Levy BI
    Am J Hypertens; 2005 Sep; 18(9 Pt 2):134S-141S. PubMed ID: 16125050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the renin-angiotensin-aldosterone system in cardiovascular progenitor cell function.
    Qian C; Schoemaker RG; van Gilst WH; Roks AJ
    Clin Sci (Lond); 2009 Feb; 116(4):301-14. PubMed ID: 19138171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sympathetic hyperactivity and cardiac dysfunction post-MI: different impact of specific CNS versus general AT1 receptor blockade.
    Huang BS; Ahmad M; Tan J; Leenen FH
    J Mol Cell Cardiol; 2007 Oct; 43(4):479-86. PubMed ID: 17714732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-sympathetic system interactions in cardiovascular and metabolic disease.
    Mancia G; Dell'Oro R; Quarti-Trevano F; Scopelliti F; Grassi G
    J Hypertens Suppl; 2006 Mar; 24(1):S51-6. PubMed ID: 16601574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interaction between the sympathetic and renin-angiotensin system].
    K-Laflamme A; de Champlain J
    Therapie; 1998; 53(3):245-52. PubMed ID: 9773124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional evidence that in the cardiovascular system AT1 angiotensin II receptors are AT1B prejunctionally and AT1A postjunctionally.
    Guimarães S; Pinheiro H
    Cardiovasc Res; 2005 Aug; 67(2):208-15. PubMed ID: 15953595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA; Wendt C; Saborowski F
    Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA
    Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers.
    Nickenig G; Ostergren J; Struijker-Boudier H
    J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S1-7. PubMed ID: 16969748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.
    Aulakh GK; Sodhi RK; Singh M
    Life Sci; 2007 Aug; 81(8):615-39. PubMed ID: 17692338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of losartan on muscle sympathetic activity and baroreceptor function in systemic hypertension.
    Béchir M; Enseleit F; Chenevard R; Lüscher TF; Noll G
    Am J Cardiol; 2005 Jan; 95(1):129-31. PubMed ID: 15619411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
    Krum H; Gilbert RE
    J Hypertens; 2007 Jan; 25(1):25-35. PubMed ID: 17143168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.